drugset / Trial / NCT07635394

Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome

NCT07635394 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).

Timeline

Start
2026-04-07
Primary completion
2026-04-08
Completion
2029-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 225 mg —
Background Dicyclomine Small molecule — —
Background Eluxadoline Small molecule 75 mg —
Background Eluxadoline Small molecule 100 mg —
Background Hyoscyamine Small molecule — —
Background Loperamide Small molecule — —
Background Rifaximin Other / unclassified 550 mg —